Skip to main content

Advertisement

SpringerLink
Log in

Optimal conditions for successful ablation of high-grade dysplasia in Barrett’s oesophagus using aminolaevulinic acid photodynamic therapy

  • Original Article
  • Published:
Lasers in Medical Science Aims and scope Submit manuscript

Abstract

Photodynamic therapy (PDT) using 5-aminolaevulinic acid (ALA-PDT) is an attractive alternative to PDT with porfimer sodium for the treatment of high-grade dysplasia (HGD) in Barrett’s oesophagus (BO) because of the shorter duration of light photosensitivity and low risk of oesophageal stricture formation. Published results, however, show marked variation in its efficacy, and optimum treatment parameters have not been defined. This study investigated how the dose of ALA and the colour of the illuminating light influenced the biological effect. Twenty-seven patients were enrolled into a randomised controlled trial of red versus green (635 nm or 512 nm) laser light activation for the eradication of HGD with ALA-PDT in Barrett’s oesophagus. A further 21 patients were subsequently treated with the most effective regimen. Regular endoscopic follow-up with quadrantic biopsies every 2 cm was performed. The primary outcome measure was eradication of HGD. Patient’s receiving ALA at 30 mg/kg relapsed to HGD more than those receiving 60 mg/kg (P = 0.03). Additionally, for those treated with ALA 60 mg/kg, red laser light was more effective than green laser light (P = 0.008). Kaplan–Meier analysis of the 21 patients who were subsequently treated with this optimal regimen demonstrated an eradication rate of 89% for HGD and a cancer-free proportion of 96% at 36 months’ follow-up. Using an ALA dose of 60 mg/kg activated by 1,000J/cm red laser light, we found that ALA-PDT was a highly effective treatment for high-grade dysplasia in Barrett’s oesophagus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Newnham A, Quinn MJ, Babb P et al (2003) Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971–1998. Aliment Pharmacol Ther 17:665–676. doi:10.1046/j.1365–2036.2003.01521.x

    Article  PubMed  CAS  Google Scholar 

  2. Montgomery E, Goldblum JR, Greenson JK et al (2001) Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32:379–388. doi:10.1053/hupa.2001.23511

    Article  PubMed  CAS  Google Scholar 

  3. Reid BJ, Levine DS, Longton G et al (2000) Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95:1669–1676

    PubMed  CAS  Google Scholar 

  4. Schnell TG, Sontag SJ, Chejfec G et al (2001) Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology 120:1607–1619. doi:10.1053/gast.2001.25065

    Article  PubMed  CAS  Google Scholar 

  5. Overholt BF, Wang KK, Burdick JS et al (2007) Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc 66:460–468. doi:10.1016/j.gie.2006.12.037

    Article  PubMed  Google Scholar 

  6. Overholt BF, Panjehpour M, Haydek JM (1999) Photodynamic therapy for Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc 49:1–7. doi:10.1016/S0016–5107(99)70437–2

    Article  PubMed  CAS  Google Scholar 

  7. Overholt BF, Panjehpour M, Halberg DL (2003) Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 58:183–188. doi:10.1067/mge.2003.327

    Article  PubMed  Google Scholar 

  8. Loh CS, MacRobert AJ, Buonaccorsi G et al (1996) Mucosal ablation using photodynamic therapy for the treatment of dysplasia: an experimental study in the normal rat stomach. Gut 38:71–78. doi:10.1136/gut.38.1.71

    Article  PubMed  CAS  Google Scholar 

  9. Regula J, MacRobert AJ, Gorchein A et al (1995) Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX—a pilot study. Gut 36:67–75. doi:10.1136/gut.36.1.67

    Article  PubMed  CAS  Google Scholar 

  10. Mackenzie GD, Jamieson NF, Novelli MR et al (2008) How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett’s esophagus. Lasers Med Sci 23:203–210

    Google Scholar 

  11. Ackroyd R, Kelty CJ, Brown NJ et al (2003) Eradication of dysplastic Barrett’s oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 35:496–501. doi:10.1055/s-2003–39676

    Article  PubMed  CAS  Google Scholar 

  12. Peters F, Kara M, Rosmolen W et al (2005) Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in barrett esophagus after endoscopic resection. Endoscopy 37:418–424. doi:10.1055/s-2005–861198

    Article  PubMed  CAS  Google Scholar 

  13. Schlemper RJ, Riddell RH, Kato Y et al (2000) The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47:251–255. doi:10.1136/gut.47.2.251

    Article  PubMed  CAS  Google Scholar 

  14. Waidelich R, Stepp H, Baumgartner R et al (2001) Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 165:1904–1907. doi:10.1016/S0022–5347(05)66239–8

    Article  PubMed  CAS  Google Scholar 

  15. Ackroyd R, Brown NJ, Davis MF et al (2000) Aminolevulinic acid-induced photodynamic therapy: safe and effective ablation of dysplasia in Barrett’s esophagus. Dis Esophagus 13:18–22. doi:10.1046/j.1442–2050.2000.00067.x

    Article  PubMed  CAS  Google Scholar 

  16. Pech O, Gossner L, May A et al (2005) Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 62:24–30. doi:10.1016/S0016–5107(05)00333–0

    Article  PubMed  Google Scholar 

  17. Peters FP, Kara MA, Rosmolen WD et al (2005) Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett’s esophagus. Gastrointest Endosc 61:506–514. doi:10.1016/S0016–5107(05)00063–5

    Article  PubMed  Google Scholar 

  18. Barr H, Shepherd NA, Dix A et al (1996) Eradication of high-grade dysplasia in columnar-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348:584–585. doi:10.1016/S0140–6736(96)03054–1

    Article  PubMed  CAS  Google Scholar 

  19. Forcione DG, Hasan T, Ortel BJ et al (2004) Optimization of aminolevulinic acid-based photodynamic therapy of Barrett’s esophagus with high grade dysplasia. Gastrointest Endosc 59:P251. doi:10.1016/S0016–5107(04)01121–6

    Article  Google Scholar 

  20. Hage M, Siersema PD, van Dekken H et al (2004) 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: a randomised trial. Gut 53:785–790. doi:10.1136/gut.2003.028860

    Article  PubMed  CAS  Google Scholar 

  21. Gossner L, Stolte M, Sroka R et al (1998) Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid. Gastroenterology 114:448–455. doi:10.1016/S0016–5085(98)70527-X

    Article  PubMed  CAS  Google Scholar 

  22. Kelty CJ, Ackroyd R, Brown NJ et al (2004) Endoscopic ablation of Barrett’s oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 20:1289–1296. doi:10.1111/j.1365–2036.2004.02277.x

    Article  PubMed  CAS  Google Scholar 

  23. Kelty CJ, Ackroyd R, Brown NJ et al (2004) Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett’s esophagus. Surg Endosc 18:452–458. doi:10.1007/s00464–003–9062–4

    Article  PubMed  CAS  Google Scholar 

  24. Ackroyd R, Brown NJ, Davis MF et al (2000) Photodynamic therapy for dysplastic Barrett’s oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 47:612–617. doi:10.1136/gut.47.5.612

    Article  PubMed  CAS  Google Scholar 

  25. Mackenzie GD, Dunn JM, Novelli MR et al (2008) Preliminary results of a randomised controlled trial into the safety and efficacy of ala versus photofrin photodynamic therapy for high grade dysplasia in Barrett’s oesophagus. Gut 57:A14

    Google Scholar 

  26. Sharma VK, Wang KK, Overholt BF et al (2007) Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 65:185–195. doi:10.1016/j.gie.2006.09.033

    Article  PubMed  Google Scholar 

  27. Rothstein RI, Chang K, Overholt BF et al (2007) Focal ablation for treatment of dysplastic and non-dysplastic Barrett esophagus: safety profile and initial experience with the Halo90 device in 508 cases. Gastrointest Endosc 65:AB147. doi:10.1016/j.gie.2007.03.198

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank DUSA Pharmaceuticals, who kindly provided the drug and lasers for the study as well as providing travel grant support for us to present the study findings. This work was undertaken at UCLH/UCL, which received a proportion of funding from the Department of Health’s National Institute for Health Research (NIHR) Biomedical Research Centres funding scheme. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.

Author information

Authors and Affiliations

  1. Department of Surgery, National Medical Laser Centre, Royal Free and University College Medical School, University College London, 67–73 Riding House Street, London, W1W 7EJ, UK

    Gary D. Mackenzie, Jason M. Dunn, C. R. Selvasekar, C. Alexander Mosse, Sally M. Thorpe, Stephen G. Bown & Laurence B. Lovat

  2. Department of Histopathology, Royal Free and University College Medical School, University College London, London, UK

    Marco R. Novelli

  3. Department of Gastroenterology, University College London Hospitals NHS Trust, London, UK

    Laurence B. Lovat

Authors
  1. Gary D. Mackenzie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason M. Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. R. Selvasekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Alexander Mosse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sally M. Thorpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marco R. Novelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stephen G. Bown
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Laurence B. Lovat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurence B. Lovat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mackenzie, G.D., Dunn, J.M., Selvasekar, C.R. et al. Optimal conditions for successful ablation of high-grade dysplasia in Barrett’s oesophagus using aminolaevulinic acid photodynamic therapy. Lasers Med Sci 24, 729–734 (2009). https://doi.org/10.1007/s10103-008-0630-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10103-008-0630-7

Keywords

Search

Navigation